BNP Paribas Upgrades Medline (NASDAQ:MDLN) to Hold

Medline (NASDAQ:MDLN) was upgraded by equities research analysts at BNP Paribas to a “hold” rating in a report released on Monday,Zacks.com reports.

Other analysts also recently issued research reports about the stock. Royal Bank Of Canada assumed coverage on shares of Medline in a report on Monday. They set an “outperform” rating and a $47.00 price target on the stock. Jefferies Financial Group began coverage on shares of Medline in a report on Monday. They set a “buy” rating and a $50.00 target price for the company. BNP Paribas Exane began coverage on Medline in a report on Monday. They issued a “neutral” rating and a $38.00 target price on the stock. Leerink Partnrs raised Medline to a “strong-buy” rating in a research note on Monday. Finally, Stifel Nicolaus initiated coverage on shares of Medline in a research note on Monday. They set a “buy” rating and a $46.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Medline currently has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Price Performance

Shares of NASDAQ:MDLN opened at $42.85 on Monday. Medline has a 1 year low of $34.89 and a 1 year high of $45.50.

Insider Transactions at Medline

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the transaction, the insider directly owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. This represents a 55.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew J. Mills purchased 2,586,206 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the purchase, the director owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple large brokers started coverage with bullish ratings and above‑current price targets (examples: Truist $52, Goldman $49, Evercore $50, Bank of America $50, Jefferies $50, JPMorgan $50) — these notes provide buy signals and set upside targets that can support continued buying interest. Jefferies Coverage Initiation Truist Initiation Evercore Note
• Positive Sentiment: Analysts highlight Medline’s scale (cited as ~$25bn supply‑chain advantage) and a strong product portfolio as durable competitive advantages — framing the company as a long‑term growth/market‑share story. Jefferies Supply Chain Article
• Neutral Sentiment: Market context: Medline raised roughly $7 billion in its IPO, giving management capital flexibility; coverage initiation breadth improves liquidity and research availability for investors. Benzinga IPO Coverage Summary
• Neutral Sentiment: Short interest is effectively zero, so downward pressure from short selling is minimal — this lowers one source of volatility but also removes a potential short‑squeeze catalyst. (Data reported as 0 shares short as of Jan 12.)
• Negative Sentiment: Some firms opened with cautious or below‑current targets (examples: BNP Paribas Exane $38, Deutsche Bank $40, Wells Fargo $42, Rothschild/Redburn $42). These notes could cap near‑term upside or prompt profit‑taking from more conservative investors. BNP Paribas Exane Coverage Deutsche Bank Coverage

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.